MOS Prebiotic Potential in Older Adults

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Final enrollment: 22 participants (planned 40)
    • Study completion date changed from estimate of Jun 30, 2026 to Sep 30, 2026
    • Eligibility criteria expanded, about 14 words
    • Publications: details revised at 1 of 1 entry
  2. Primary completion date changed from estimate of Sep 30, 2025 to Feb 28, 2024
    • Study completion date: Dec 31, 2025 to Jun 30, 2026
    v8
  3. Primary completion date: Dec 31, 2024 to Sep 30, 2025
    • Study completion date: Mar 31, 2025 to Dec 31, 2025
    v7
  4. Enrollment target: 22 to 40
    • Primary completion date: Feb 28, 2024 to Dec 31, 2024
    • Study completion date: Aug 31, 2024 to Mar 31, 2025
    • Eligibility criteria expanded, about 9 words
    v6
  5. Re-verified, no change to tracked fieldsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 22
    • Site details revised
    v4
  2. Primary completion date: Dec 31, 2023 to Feb 28, 2024
    • Study completion date: Mar 31, 2024 to Aug 31, 2024
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria revised
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.
Trial Details
NCT Number NCT05939336
Lead Sponsor University of Florida
Collaborators: Lallemand Bio-Ingredients
Conditions
(from sponsor)		 Healthy
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov